Cost-effectiveness analysis of treatments for the first episode of catastrophic antiphospholipid syndrome: A study based on the catastrophic antiphospholipid syndrome registry

1. Asherson, RA . The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19(4): 508–512.
Google Scholar | Medline2. Cervera, R, Piette, JC, Font, J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46(4): 1019–1027. DOI: 10.1002/art.10187.
Google Scholar | Crossref | Medline3. Cervera, R, Rodríguez-Pintó, I, Espinosa, G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun 2018; 92: 1–11. DOI: 10.1016/j.jaut.2018.05.007.
Google Scholar | Crossref | Medline4. Bucciarelli, S, Espinosa, G, Cervera, R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54(8): 2568–2576. DOI: 10.1002/art.22018.
Google Scholar | Crossref | Medline5. Cervera, R, Rodríguez-Pintó, I, Legault, K, Erkan, D. 16th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Lupus 2020; 29(12): 1594–1600. DOI: 10.1177/0961203320951260.
Google Scholar | SAGE Journals | ISI6. Unlu, O, Erkan, D. Catastrophic antiphospholipid syndrome: candidate therapies for a potentially lethal disease. Annu Rev Med 2017; 68: 287–296. DOI: 10.1146/annurev-med-042915-102529.
Google Scholar | Crossref | Medline7. Sanders, GD, Maciejewski, ML, Basu, A. Overview of cost-effectiveness analysis. JAMA 2019; 321(14): 1400–1401. DOI: 10.1001/jama.2019.1265.
Google Scholar | Crossref | Medline8. Brooke, BS, Kaji, AH, Itani, KMF. Practical guide to cost-effectiveness analysis. JAMA Surg 2020; 155(3): 250–251. DOI: 10.1001/jamasurg.2019.4392.
Google Scholar | Crossref | Medline9. Legault, K, Schunemann, H, Hillis, C, et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost 2018; 16: 1656–1664. DOI: 10.1111/jth.1419210.1111/jth.14192.
Google Scholar | Crossref10. Instituto de Evaluación Tecnológica en Salud . Manual metodológico para la elaboración de evaluaciones de efectividad, seguridad y validez diagnóstica de tecnologías en salud. Bogota, Colombia: Instituto de Evaluación Tecnológica en Salud; 2014.
Google Scholar11. Cervera, R, Rodríguez-Pintó, I, Colafrancesco, S, et al. 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev 2014; 13(7): 699–707. DOI: 10.1016/j.autrev.2014.03.002.
Google Scholar | Crossref | Medline12. Minsalud Colombia . Consulta Pública de Precios de Medicamentos en la Cadena de Comercialización (Minsalud Colombia. Public Consultation of Drug Prices in the Marketing Chain) [Internet]. Bogota, Colombia: Ministerio de Salud y Protección Social. Web.sispro.gov.co. 2019. Available from: https://web.sispro.gov.co/WebPublico/Consultas/ConsultarCNPMCadenaComercializacionCircu2yPA_028_2_2.aspx (Accessed January 2019)
Google Scholar13. Banco de la República de Colombia . Tasa de cambio del peso colombiano (TRM). Bogota, Colombia: Banco de la República de Colombia. https://www.banrep.gov.co/es/estadisticas/trm (2020, (Accessed February 2020)
Google Scholar14. Banco de la República de Colombia . PRODUCTO INTERNO BRUTO TOTAL Y POR HABITANTE (A Precios Corrientes) Año Base 2015. Bogota, Colombia: Banco de la República de Colombia. 2015, https://www.banrep.gov.co/es/estadisticas/producto-interno-bruto-pib
Google Scholar15. Rodríguez-Pintó, I, Espinosa, G, Erkan, D, Shoenfeld, Y, Cervera, R, CAPS Registry Project Group. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology (Oxford) 2018; 57(7): 1264–1270. DOI: 10.1093/rheumatology/key082.
Google Scholar | Crossref | Medline16. Berman, H, Rodríguez-Pintó, I, Cervera, R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013; 12(11): 1085–1090. DOI: 10.1016/j.autrev.2013.05.004.
Google Scholar | Crossref | Medline17. Espinosa, G, Berman, H, Cervera, R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011; 10(11): 664–668. DOI: 10.1016/j.autrev.2011.04.031.
Google Scholar | Crossref | Medline18. Ortel, TL, Erkan, D, Kitchens, CS. How I treat catastrophic thrombotic syndromes. Blood 2015; 126(11): 1285–1293. DOI: 10.1182/blood-2014-09-551978.
Google Scholar | Crossref | Medline19. Rodríguez-Pintó, I, Lozano, M, Cid, J, Espinosa, G, Cervera, R. Plasma exchange in catastrophic antiphospholipid syndrome. Presse Med 2019; 48(11 Pt 2): 347–353. DOI: 10.1016/j.lpm.2019.10.003.
Google Scholar | Crossref | Medline20. Cervera, R, Bucciarelli, S, Plasín, MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry. J Autoimmun 2009; 32(3–4): 240–245. DOI: 10.1016/j.jaut.2009.02.008.
Google Scholar | Crossref | Medline | ISI21. Cervera, R . CAPS Registrygistry. Lupus 2012; 21(7): 755–757. DOI: 10.1177/0961203312436866.
Google Scholar | SAGE Journals | ISI

留言 (0)

沒有登入
gif